Oppenheimer analyst Mohan Naidu lowered his price target for Tabula Rasa HealthCare to $88 from $97, while reiterating an Outperform rating on the shares after the company announced the acquisition of PrescribeWellness for $150M in cash. The analyst believes the acquisition should provide leverage to Tabula Rasa HealthCare in pushing its solutions into the pharmacies and expanding on PrescribeWellness's relationships to push the company's solutions, and should add high margin service revenues to the numbers, with Naidu expecting growth in about 20% range.